His team has developed new uses of LAB as live delivery vehicles to improve human health and has acquired a leadership position in such recombinant LAB (recLAB). He has participated in numerous national and European research projects and has strong research collaborations with agro-food and pharmaceutical companies. 

Philippe Langella is intensely involved in both commensals and probiotics domains to understand the mechanisms of these bacteria better and to enhance their use in human and animal health. Philippe Langella has authored 250 peer-reviewed international publications on the interface between microbiology and human health (WoK h-index 64). He’s the co-inventor of 26 patents in the domain of the use of commensal and probiotic bacteria in the health domain. 

Building on his groundbreaking research into Faecalibacterium prausnitzii (Fprau) and its role in microbiome-related diseases, he co-founded a biotech startup to translate these discoveries into novel therapies. Together with Pr Sokol and Pr Gervais, respectively professor gastroenterologist at Saint Antoine Hospital in Paris and professor at  AgroSup Dijon—they pioneered EXL01, a first-in-class immunomodulator derived from F. prausnitzii. Their work led to the establishment of Nextbiotix, later rebranded as Exeliom Biosciences in 2019 under the leadership of CEO Benjamin Hadida. Today, Exeliom is advancing EXL01 as a promising therapeutic candidate for Crohn’s disease and recurrent Clostridioides difficile infections, while also exploring its potential to enhance cancer immunotherapy efficacy.